Yale University has developed the intellectual property behind Anteros and was first in-licenced by BMS and later authorised to Anteros. BioMotiv CEO Dr Satish Jindal said: “Anteros Pharmaceuticals
AJOVY is under development in Japan by Otsuka Pharmaceutical Co., Ltd. (Otsuka) as part of a May 2017 exclusive license agreement for development and sales of AJOVY in
Established in 2011, MaSTherCell Global is a technology-focused cell and gene therapy contract development and manufacturing organisation (CDMO) that serves cell therapy innovators. Catalent chair and CEO John
RUXIENCE is a monoclonal antibody (mAb) for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA),
Under the deal, GSK will provide its pandemic vaccine adjuvant technology to enhance the development of an effective vaccine against 2019-nCoV virus. Coronaviruses are a family of viruses
The study, part of the TRuE-AD clinical trial program, met its primary endpoint. Significantly more patients treated with ruxolitinib cream 0.75% and 1.5% achieved Investigator’s Global Assessment Treatment
Achillion is mainly focused on the advancement of its oral small molecule complement inhibitors into late-stage development and commercialisation. The deal adds Alexion’s product portfolio with two clinical-stage
DIFICID is a macrolide antibacterial medicine indicated in adults and pediatric patients aged 6 months and older for treatment of CDAD. To reduce the development of drug-resistant bacteria
Under the deal, Atnahs will purchase global commercial rights related to AstraZeneca’s Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose
The integration of a multi-system robotics platform with sophisticated software control architecture will enable a digital transformation and accelerated discovery for Novo Nordisk’s peptide and large molecule therapeutics
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.